| 词条 | Pexidartinib |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N[6-(trifluoromethyl)-3-pyridinyl]methyl2-pyridinamine | image = Pexidartinib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = By mouth | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1029044-16-3 | class = | ATCvet = | ATC_prefix = None | ATC_suffix = | PubChem = 25151352 | DrugBank = | ChemSpiderID = 35308322 | UNII = 6783M2LV5X | KEGG = D11270 | C=20|H=15|Cl=1|F=3|N=5 | smiles = c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F | StdInChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29) | StdInChIKey=JGWRKYUXBBNENE-UHFFFAOYSA-N }}Pexidartinib (PLX-3397) is a CSF1R inhibitor drug in development by Plexxikon[1][2] for the treatment of tenosynovial giant cell tumors.[3] It is in a phase 3 clinical trial for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS).[4] References1. ^Adis Insight drug profile: Pexidartinib {{antineoplastic-drug-stub}}2. ^Microglial Magic: Drug Wipes Them Out, New Set Appears (PLX3397) 3. ^{{cite news | url = http://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-for-daiichi-sankyo-and-plexxikons-investigational-csf-1r-inhibitor-pexidartinib-plx3397-in-tenosynovial-giant-cell-tumor-300169556.html | title = FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor | date = October 30, 2015}} 4. ^[https://clinicaltrials.gov/ct2/show/NCT02371369 Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) (ENLIVEN)] 4 : Protein kinase inhibitors|Pyridines|Experimental cancer drugs|Trifluoromethyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。